Market closed
Lantheus/$LNTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lantheus
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Ticker
$LNTH
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
808
Website
Lantheus Metrics
BasicAdvanced
$7.1B
23.77
$4.36
0.44
-
Price and volume
Market cap
$7.1B
Beta
0.44
52-week high
$126.89
52-week low
$63.76
Average daily volume
748K
Financial strength
Current ratio
5.516
Quick ratio
5.131
Long term debt to equity
57.762
Total debt to equity
57.852
Interest coverage (TTM)
22.67%
Management effectiveness
Return on assets (TTM)
15.35%
Return on equity (TTM)
32.82%
Valuation
Price to earnings (TTM)
23.771
Price to revenue (TTM)
4.675
Price to book
6.52
Price to tangible book (TTM)
8.2
Price to free cash flow (TTM)
17.398
Growth
Revenue change (TTM)
18.32%
Earnings per share change (TTM)
-6.24%
3-year revenue growth (CAGR)
53.37%
3-year earnings per share growth (CAGR)
60.22%
What the Analysts think about Lantheus
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Lantheus stock.
Lantheus Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Lantheus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Lantheus News
AllArticlesVideos
Lantheus to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025, at 8:00 a.m. Eastern Time
GlobeNewsWire·2 days ago
Lantheus Completes Acquisition of Evergreen Theragnostics
GlobeNewsWire·3 weeks ago
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Lantheus stock?
Lantheus (LNTH) has a market cap of $7.1B as of April 25, 2025.
What is the P/E ratio for Lantheus stock?
The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 23.77 as of April 25, 2025.
Does Lantheus stock pay dividends?
No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Lantheus dividend payment date?
Lantheus (LNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantheus?
Lantheus (LNTH) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.